• Saniona completed preclinical and manufacturing work needed to support Phase 1 development of SAN2668 for severe pediatric epilepsies.
• Preclinical results announced today support potential seizure control with improved tolerability; clinical testing remains planned.
• A clinical trial application is planned for submission through the EU Clinical Trials Information System by the end of December 2026.
• The planned Phase 1 study will assess safety, tolerability and pharmacokinetics in healthy volunteers.
• A planned proof-of-mechanism study in patients with photosensitive epilepsy will help guide Phase 2 dose selection alongside the healthy-volunteer study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Saniona AB published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.